Pfizer Inc. at Morgan Stanley Global Healthcare Conference Transcript
Great. Good morning. Thanks for joining us. I'm Terence Flynn, Morgan Stanley's US Biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Well, I'm very pleased to be hosting Pfizer this morning at our conference. Thanks so much to Albert Bourla, who's the company's CEO and Chairman. I'm very happy to be here with you, Albert. And maybe I'll turn over to you to just make some opening remarks before we launch into Q&A. But again, thanks for taking time out of your day.
Thank you for the invitation. Good morning, everyone. I mean, very few comments in the beginning, I think that Pfizer is in a good place right now. We had three serious headwinds in 2025 that I think
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
